READ: Featured Drug Insights: July 2025 - Prime Therapeutics
READ: Featured Drug Insights: July 2025
Your source for all Prime Therapeutics' June 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for July 2025 will keep you informed on what’s trending now and trending clinical topics.
Released July 3, 2025
Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features Rebisufligene etisparvovec (UX111), an in vivo gene therapy to help treat patients with Sanfilippo A syndrome.
Released July 14, 2025
Featuring commentary by Abby Kim, PharmD, BCOP on developments in the oncology space, this installment explores pivotal clinical trials, their outcomes and the potential impact they will have on the managed care landscape.
Released July 16, 2025
FDA Decisions Expected: August 2025
A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers denosumab, doxecitine/doxribtimine, etripamil and more.
Released July 30, 2025
Trending Topics & Drug Approvals: July 2025
We've combined Clinical Highlights and Drug Approvals into this new, monthly publication, which covers the latest specialty and traditional drug approvals. The latest edition features a national update on the rising number of U.S. measles cases, which have now surpassed 1,300 in 2025.
Released July 31, 2025
Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well-sourced on the drug pipeline.
Released Aug. 4, 2025
Prime provides a quarterly drug pipeline report of anticipated new drugs, deep dives and indications for the following pipelines: traditional, specialty drugs, biosimilars, and gene and cell therapy.
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
All brand names are property of their respective owners.